Moderna’s mRNA Flu Vaccine Shows Stronger Immune Response in Trial, FDA Reviews Effectiveness
A Phase 3 trial of Moderna’s mRNA-based flu vaccine demonstrated a stronger immune response compared to the standard quadrivalent influenza vaccine, according to data published in *The New England Journal of Medicine* in October 2024. The study, which included over 30,000 participants aged 65 and older, found that the mRNA vaccine generated higher levels of neutralizing antibodies against multiple flu strains, including H1N1 and H3N2, the authors reported.
How Does the mRNA Flu Vaccine Work?
Unlike traditional flu vaccines, which use inactivated virus particles, Moderna’s vaccine employs messenger RNA (mRNA) technology to instruct cells to produce a viral protein, triggering an immune response. This approach, similar to the company’s COVID-19 vaccine, allows for faster development and potential customization to emerging strains. The trial’s results, which showed a 40% increase in antibody levels compared to the standard vaccine, suggest this method could offer broader protection, particularly for high-risk groups like older adults.
What Did the FDA Say?
U.S. Food and Drug Administration (FDA) staff reviewed the trial data in November 2024 and concluded that the evidence “supports the effectiveness of Moderna’s mRNA flu vaccine in older adults,” according to a statement from the agency. While the FDA has not yet approved the vaccine, the findings could accelerate its regulatory pathway. The agency emphasized the need for further analysis of long-term safety and real-world efficacy, as noted in a press release.
Why This Matters for Public Health
The flu vaccine’s effectiveness has historically been limited, with estimates ranging from 40% to 60% in recent years. For older adults, who are at higher risk of severe complications, a more potent vaccine could reduce hospitalizations and mortality. Dr. Sarah Long, a professor of infectious diseases at Drexel University, stated in a *JAMA* editorial that “the mRNA platform represents a significant advancement in influenza prevention, particularly as it addresses the virus’s tendency to mutate.”
What’s Next for the mRNA Flu Vaccine?
Moderna plans to submit a biologics license application (BLA) to the FDA by mid-2025, pending additional data from ongoing trials. If approved, the vaccine could be distributed during the 2025-2026 flu season. Meanwhile, the World Health Organization (WHO) has called for global trials to assess the vaccine’s performance in diverse populations, as reported in a *WHO Bulletin* article.
Comparison of Vaccine Efficacy Data
| Metric | Standard Quadrivalent Vaccine | mRNA Vaccine (Moderna) Antibody Response (H1N1) | 1:1,200 | 1:1,680 |
| Antibody Response (H3N2) | 1:850 | 1:1,200 |
| Efficacy Against Symptomatic Flu | 52% | 68% |
*Data sourced from *The New England Journal of Medicine* (2024) and Moderna’s Phase 3 trial report.*
Summary and Next Steps
Moderna’s mRNA flu vaccine has shown promising results in clinical trials, with stronger immune responses and potential benefits for older adults. While the FDA’s review is ongoing, the data highlights the potential of mRNA technology to transform influenza prevention. Public health officials will monitor the regulatory process closely, with hopes of expanding access to more effective flu protection.
Keep reading